IL17A and psoriasis vulgaris: Secukinumab is a fully human monoclonal antibody that selectively targets interleukin-17A (IL-17A) and is approved for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy (1).